USPTO Patent Application for PSMA Ligands
Summary
The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.
What changed
The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260083865A1, filed on September 6, 2023, by 3B Pharmaceuticals GMBH. The application pertains to prostate specific membrane antigen (PSMA) ligands and their use, specifically disclosing a compound of Formula (I).
This publication represents a new patent filing and does not impose immediate regulatory obligations on entities. However, it signifies potential future intellectual property developments in the pharmaceutical sector related to cancer therapeutics. Companies operating in this space should be aware of this filing as it may impact future research, development, and commercialization strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF
Application US20260083865A1 Kind: A1 Mar 26, 2026
Assignee
3B Pharmaceuticals GMBH
Inventors
Anne BREDENBECK, Christian Haase, Dirk Zboralski, Eberhard Schneider, Ina Wilkening, Jan Ungewiss, Jessica Wahsner-Teschner, Judith Weber, Mattias Paschke, Naowras Al-Obaidi
Abstract
The present disclosure is related to a compound of Formula (I)
CPC Classifications
A61K 51/088 A61P 35/00 A61K 2121/00 A61K 2123/00
Filing Date
2023-09-06
Application No.
19109312
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.